SUNDAY, SEPTEMBER 30, 2018

8:30 a.m.-8:45 a.m.
Welcome
Broadway Ballroom (Sixth Floor)

Jill O’Donnell-Tormey, Cancer Research Institute, New York, NY

8:45 a.m.-11:45 a.m.
Session 1: Regulating T Cells and Their Response to Cancer
Broadway Ballroom (Sixth Floor)

Session Chair: Christoph Huber, Association for Cancer Immunotherapy (CIMT), Mainz, Germany

8:45 a.m.  T-cell exhaustion and PD-1 therapy
Rafi Ahmed, Emory University, Atlanta, GA

9:15 a.m.  Tissue resident memory cells: At the center of tumor control
Christian Ottensmeier, University of Southampton, Southampton, United Kingdom

9:45 a.m.  Refreshment Break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

10:15 a.m. Genetic screens for immunotherapy target discovery
W. Nicholas Haining, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m. Dysfunction and stemness of tumor-infiltrating T cells are triggered by a common mechanism
Nicholas P. Restifo, National Cancer Institute, NIH, Bethesda, MD
11:15 a.m.  PR1 Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients*
Roberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, NY

11:30 a.m.  PR2 Neoadjuvant immunotherapy precancer surgery relieves tumor-specific CD8+ T-cell dysfunction and restores memory differentiation potential*
Jake S. O’Donnell, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

11:45 a.m.-2:15 p.m.  Lunch and Poster Session A and Exhibits
Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Clinical Trials of Cancer Immunotherapies
Genetically Engineered T Cells
Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
Regulating T Cells and Their Response to Cancer
Tackling the Tumor Microenvironment - Beyond T Cells

2:15 p.m.-2:45 p.m.  William B. Coley Lecture
Broadway Ballroom (Sixth Floor)

From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX

*Short talk from proffered abstract
2:45 p.m.-6:15 p.m.
Session 2: Tackling the Tumor Microenvironment – Beyond T Cells
Broadway Ballroom (Sixth Floor)

Session Cochairs: Wolf H. Fridman, Centre de Recherche des Cordeliers, Paris, France, and Dmitry Gabrilovich, The Wistar Institute, Philadelphia, PA

2:45 p.m.  
Stromal activation in cancer immunology and immunotherapy  
Shannon J. Turley, Genentech, South San Francisco, CA

3:15 p.m.  
Using matrix protein affinity to modulate the tumor microenvironment  
Jeffrey A. Hubbell, University of Chicago, Chicago, IL

3:45 p.m.  
The tumor myeloid microenvironment  
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY

4:15 p.m.  
Refreshment Break  
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

4:45 p.m.  
Harnessing natural and engineered properties of NKT cells for cancer immunotherapy  
Leonid S. Metelitsa, Baylor College of Medicine, Houston, TX

5:15 p.m.  
PMN-MDSC and neutrophils: Tale of two cells in cancer  
Dmitry Gabrilovich

5:45 p.m.  
PR3 Immune-based classification of soft-tissue sarcoma is associated with clinical outcome and unveils tertiary lymphoid structures as surrogate biomarker for the clinic*  
Wei-Wu Tom Chen, National Taiwan University Hospital, Taipei, Taiwan

*Short talk from proffered abstract
6:00 p.m.   PR4 A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments*  
Kevin C. Barry, University of California, San Francisco, San Francisco, CA

MONDAY, OCTOBER 1, 2018

8:15 a.m.-8:45 a.m.  
**Keynote Address**  
Broadway Ballroom (Sixth Floor)

The immunotherapy faces of Interleukin-8 and CD137  
Ignacio Melero, Universidad de Navarra, University Clinic and CIMA, Pamplona, Spain

8:45 a.m.-12:45 p.m.  
**Session 3: Genetically Engineered T Cells**  
Broadway Ballroom (Sixth Floor)

**Session Cochairs:** Crystal L. Mackall, Stanford University School of Medicine, Stanford, CA, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY

8:45 a.m.  
**CAR T-cell therapy for lymphoma and multiple myeloma**  
James N. Kochenderfer, National Cancer Institute, NIH, Bethesda, MD

9:15 a.m.  
**Engineering exhaustion-resistant CAR T cells**  
Crystal L. Mackall

9:45 a.m.  
**Cell transfer immunotherapy targeting unique somatic mutations in cancer**  
Steven A. Rosenberg, National Cancer Institute, NIH, Bethesda, MD

*Short talk from proffered abstract
10:15 a.m. Refreshment Break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

10:45 a.m. Advancing CAR T cell therapy for the treatment of brain tumors
Christine E. Brown, City of Hope National Medical Center, Duarte, CA

11:15 a.m. Novel approaches to CAR T-cell engineering
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

11:45 a.m. Utilizing synthetic biology and high-dimension probing to address therapeutic obstacles and empower engineered T cells with the capacity to eradicate tumors
Philip D. Greenberg, Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA

12:15 p.m. PR5 T cells engineered to overcome death signaling within the tumor microenvironment enhance adoptive cancer immunotherapy*
Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, New York, NY

12:30 p.m. PR6 Dual-specific T cells and an indirect vaccine eradicate large solid tumors*
Clare Y. Slaney, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

12:45 p.m.-2:15 pm. Lunch and Exhibits
Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

*Short talk from proffered abstract
CONFERENCE SCHEDULE

2:15 p.m.-5:45 p.m.
Session 4: Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
Broadway Ballroom (Sixth Floor)

Session Cochairs: Catherine Sautès-Fridman, Université Paris-Descartes, Paris, France, and Ellen Puré, University of Pennsylvania, Philadelphia, PA

2:15 p.m. Inactivation of DNA repair to improve immune surveillance
Alberto Bardelli, University of Turin and Candiolo Cancer Institute, Candiolo, Italy

2:45 p.m. CAR T cells: On the road to a cure
David L. Porter, University of Pennsylvania, Philadelphia, PA

3:15 p.m. Targeting the immune microenvironment in breast cancer
Peter Savas, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

3:45 p.m. RNA-editing derived epitopes function as cancer antigens to elicit immune responses
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX

4:15 p.m. Refreshment break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

4:45 p.m. Autoimmune rheumatic diseases and cancer
Antony Rosen, Johns Hopkins University School of Medicine, Baltimore, MD

5:15 p.m. PR7 Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone mice*
Arabella Young, University of California San Francisco, San Francisco, CA

*Short talk from proffered abstract
5:30 p.m.  PR8 Mechanisms of primary resistance to PD-1 checkpoint blockade*
Michelle Krogsgaard, NYU School of Medicine, New York, NY

TUESDAY, OCTOBER 2, 2018

8:15 a.m.-12:45 p.m.  Session 5: Novel Vaccine Platforms and Combinations
Broadway Ballroom (Sixth Floor)

Session Cochairs: Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY, and Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals, Leiden, The Netherlands

8:15 a.m.  High-dimensional analysis of effective cancer immunotherapy driven by MHC-I and MHC-II neoepitopes
Matthew M. Gubin, Washington University School of Medicine, St. Louis, MO

8:45 a.m.  Personalized cancer immunotherapy
Ugur Sahin, BioNTech, Mainz, Germany  *(not eligible for CME credit)*

9:15 a.m.  Targeting tumor neoantigens to drive effective tumor immunity
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

9:45 a.m.  Combination immunotherapy of cancer caused by human papilloma virus
Cornelis J.M. Melief

10:15 a.m.  Refreshment Break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

*Short talk from proffered abstract*
10:45 a.m.  Oncolytic viruses: Potential for in situ antitumor vaccination and combination with checkpoint blockade
Alan Melcher, The Institute of Cancer Research, London, United Kingdom

11:15 a.m.  Nanodisc platform technology for cancer vaccination
James J. Moon, University of Michigan, Ann Arbor, MI

11:45 a.m.  Peptide-TLR-7/8 agonist conjugate vaccines chemically programmed for nanoparticle self-assembly to enhance the magnitude and breadth of anticancer neoantigen CD8 T cell immunity
Robert Seder, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

12:15 p.m.  PR9 Intratumoral delivery of engineered modified vaccinia virus Ankara expressing Flt3L and OX40L for in situ therapeutic cancer vaccination*
Liang Deng, Memorial Sloan Kettering Cancer Center, New York, NY

12:30 p.m.  PR10 Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy*
Elizabeth C. Evans, Vaccinex, Inc., Rochester, NY

12:45 p.m.-3:15 p.m.  
Lunch and Poster Session B and Exhibits
Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Convergence of Technology and Cancer Immunotherapy
Microbiome and Metabolism

*Short talk from proffered abstract
Mutational Analysis and Predicting Response to Immunotherapy

Novel Vaccine Platforms and Combinations

Trials in Progress

Other

3:15 p.m.-6:45 p.m.
Session 6: Mutational Analysis and Predicting Response to Immunotherapy
Broadway Ballroom (Sixth Floor)

Session Cochairs: Drew M. Pardoll, Johns Hopkins University School of Medicine, Baltimore, MD, and Ton N. Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands

3:15 p.m. T-cell recognition in human cancer
Ton N. Schumacher

3:45 p.m. Measuring the emergence of non-self in tumors
Benjamin D. Greenbaum, Icahn School of Medicine at Mount Sinai, New York, NY

4:15 p.m. Application of TMB in the clinic to predict response to immunotherapy
Naiyer Rizvi, Columbia University Medical Center, New York, NY

4:45 p.m. Refreshment break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

5:15 p.m. Cancer genetics and response to immunotherapy
Drew M. Pardoll

5:45 p.m. Mapping immune recognition of non-self neoantigens in human pancreatic cancer
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY
CONFERENCE SCHEDULE
Session 6 (cont’d)

6:15 p.m.  PR11 CX3CR1+CD8+ T cells are responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade*
Yiyi Yan, Mayo Clinic College of Medicine, Rochester, MN

6:30 p.m.  PR12 Functional identification and therapeutic targeting of tumor neoantigens*
Stephen Philip Schoenberger, La Jolla Institute for Allergy and Immunology, La Jolla, CA

WEDNESDAY, OCTOBER 3, 2018

8:15 a.m.-10:45 a.m.  Session 7: Convergence of Technology and Cancer Immunotherapy
Broadway Ballroom (Sixth Floor)

Session Cochairs: Carl G. Figdor, Radboud University Nijmegen, Nijmegen, The Netherlands, and Özlem Türeci, Ganymed Pharmaceuticals, Mainz, Germany

8:15 a.m.  Determinants of effective tumor immunity
Nir Hacohen, Massachusetts General Hospital and Broad Institute, Cambridge, MA

8:45 a.m.  Microengineered physiologic biomimicry: Human organs-on-chips
Dan Dongeun Huh, University of Pennsylvania, Philadelphia, PA

*Short talk from proffered abstract
9:15 a.m. Enhancing the function of CAR T cells via a universal vaccine strategy
Darrell Irvine, MIT/Koch Institute for Integrative Cancer Research, Cambridge, MA

9:45 a.m. PR13 A new high-performance HLA ligand identification strategy enables prediction of T-cell tolerance to neoepitopes*
Martin G. Klatt, Memorial Sloan Kettering Cancer Center, New York, NY

10:00 a.m. PR14 Identification of specificity TCR groups of tumor antigen-specific T cells*
Liang Chen, Stanford University, Stanford, CA

10:15 a.m. Refreshment break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

10:45 a.m.-12:45 p.m. Session 8: Microbiome and Metabolism
Broadway Ballroom (Sixth Floor)

Session Cochairs: Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France, and Laurence Zitvogel, Institut Gustave Roussy, Paris, France

10:45 a.m. Manipulating the gut microbiome to improve immunotherapy of melanoma
Hassane M. Zarour, University of Pittsburgh School of Medicine, Pittsburgh, PA

11:15 a.m. Targeting the gut and tumor microbiome in response and toxicity to cancer therapy
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

*Short talk from proffered abstract
11:45 a.m.  Control of tissue immunity and repair by the microbiome
Yasmine Belkaid, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

12:15 p.m.  PR15 The oncometabolite R-2-hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via Aryl Hydrocarbon Receptor signaling*
Mirco Friedrich, German Cancer Research Center (NI), Heidelberg, Germanys

12:30 p.m.  PR16 Mucosal-associated invariant T cells respond to the cutaneous microbiota and promote skin immunity*
Michael G. Constantinides, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

12:45 p.m.-1:00 p.m.  Closing Remarks
Broadway Ballroom (Sixth Floor)
Margaret Foti, American Association for Cancer Research, Philadelphia, PA

1:00 p.m.  Meeting Ends

*Short talk from proffered abstract